GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Insider Ownership

OKUR (OnKure Therapeutics) Insider Ownership : 0.95 % (As of Apr. 28, 2025)


View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OnKure Therapeutics's insider ownership is 0.95%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OnKure Therapeutics's Institutional Ownership is 88.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OnKure Therapeutics's Float Percentage Of Total Shares Outstanding is 70.23%.


OnKure Therapeutics Insider Ownership Historical Data

The historical data trend for OnKure Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics Insider Ownership Chart

OnKure Therapeutics Historical Data

The historical data trend for OnKure Therapeutics can be seen below:

2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Insider Ownership 0.09 0.96 0.96 0.96 0.96 0.95

OnKure Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


OnKure Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.